

Title (en)
QUINAZOLINE DERIVATIVES, MEDICAMENTS CONTAINING THESE COMPOUNDS, THEIR USE, AND METHODS FOR THE PRODUCTION THEREOF

Title (de)
CHINAZOLIN DERIVATE , DIESE VERBINDUNGEN ENTHALTENDE ARZNEIMITTEL, DEREN VERWENDUNG UND VERFAHREN ZU IHRER HERSTELLUNG

Title (fr)
DERIVES DE QUINAZOLINE, MEDICAMENTS CONTENANT LESDITS COMPOSES, LEUR UTILISATION ET PROCEDES PERMETTANT DE LES PRODUIRE

Publication
EP 1315717 A1 20030604 (DE)

Application
EP 01962953 A 20010818

Priority
• DE 10042060 A 20000826
• EP 0109537 W 20010818

Abstract (en)
[origin: WO0218373A1] The invention relates to bicyclic heterocycles of general formula (I), in which Ra, Rb, Rc and n are defined as referred to in Claim No. 1, to their tautomers, their stereoisomers, and to their salts, particularly their physiologically compatible salts with inorganic or organic acids or bases, which have valuable pharmacological properties, in particular, an inhibitive effect on the signal transduction imparted by tyrosine kinases. The invention also relates to the use of said bicyclic heterocycles for treating diseases, especially tumor diseases, disorders of the lung and of the respiratory tract, and to the production thereof.

IPC 1-7
C07D 405/12; **C07D 413/12**; **C07D 413/14**; **A61K 31/517**; **C07D 239/94**

IPC 8 full level
C07D 239/04 (2006.01); **A61K 31/505** (2006.01); **A61K 31/517** (2006.01); **A61K 31/5377** (2006.01); **A61P 1/00** (2006.01); **A61P 1/04** (2006.01); **A61P 1/16** (2006.01); **A61P 1/18** (2006.01); **A61P 11/00** (2006.01); **A61P 11/02** (2006.01); **A61P 11/06** (2006.01); **A61P 11/14** (2006.01); **A61P 13/12** (2006.01); **A61P 17/00** (2006.01); **A61P 17/06** (2006.01); **A61P 29/00** (2006.01); **A61P 35/00** (2006.01); **A61P 35/04** (2006.01); **A61P 37/02** (2006.01); **A61P 37/08** (2006.01); **C07D 239/94** (2006.01); **C07D 405/12** (2006.01); **C07D 413/12** (2006.01); **C07D 413/14** (2006.01)

CPC (source: EP)
A61K 31/505 (2013.01); **A61P 1/00** (2017.12); **A61P 1/04** (2017.12); **A61P 1/16** (2017.12); **A61P 1/18** (2017.12); **A61P 11/00** (2017.12); **A61P 11/02** (2017.12); **A61P 11/06** (2017.12); **A61P 11/14** (2017.12); **A61P 13/00** (2017.12); **A61P 13/12** (2017.12); **A61P 17/00** (2017.12); **A61P 17/06** (2017.12); **A61P 29/00** (2017.12); **A61P 35/00** (2017.12); **A61P 35/04** (2017.12); **A61P 37/02** (2017.12); **A61P 37/08** (2017.12); **C07D 239/94** (2013.01); **C07D 405/12** (2013.01); **C07D 413/12** (2013.01); **C07D 413/14** (2013.01)

Citation (search report)
See references of WO 0218373A1

Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

DOCDB simple family (publication)
WO 0218373 A1 20020307; AU 8402101 A 20020313; CA 2417050 A1 20020307; CA 2417050 C 20090414; DE 10042060 A1 20020307; EP 1315717 A1 20030604; JP 2004517048 A 20040610; MX PA03000873 A 20030606

DOCDB simple family (application)
EP 0109537 W 20010818; AU 8402101 A 20010818; CA 2417050 A 20010818; DE 10042060 A 20000826; EP 01962953 A 20010818; JP 2002523888 A 20010818; MX PA03000873 A 20010818